2025 Q2 -tulosraportti
212 päivää sitten
‧37 min
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 200 | - | - | ||
| 1 400 | - | - | ||
| 1 500 | - | - | ||
| 651 | - | - | ||
| 7 445 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2025 Q4 -tulosraportti 15.4. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 | ||
2023 Q3 -tulosraportti 9.11.2023 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·1 t sittenI'm very new to the game, but I've read up as much as I can on the stock. Nevertheless, I'm struggling to figure out what to do when it comes to when I should sell - yes, I can afford to lose the money, but it's still annoying. Does anyone have an opinion on what might happen this week, before Easter fully kicks off? I'm very keen to hold onto the stock as long as there is positive news
2 t sitten2 t sitten
·4 t sitten · MuokattuWhat do people think about CRNA now before Easter? I personally have rock-solid faith in CRNA, both in the short and long term. But do you think we'll see more buying pressure ig FOMO leading up to the Easter market close, or that people will secure profits and call it a day?
·6 t sittenI see that Collao finds it exciting to follow Circio at ASGCT's annual conference in Boston. Perhaps not everyone fully understands why. ASGCT profiling practically means that a company gains visibility and professional legitimacy at ASGCT, which is the largest and most central conference in gene and cell therapy. ASGCT describes the annual meeting as the largest and most comprehensive event in the field, with 7,000+ participants, 320+ exhibitors, and an audience that includes researchers, industry leaders, regulators, and clinicians. For Circio, it more specifically means three things: 1. Professional validation If an abstract is accepted, and especially if it is chosen for oral presentation, it is a mark of quality. Circio announced on March 18, 2026, that they had submitted two abstracts to ASGCT 2026, where one was chosen for oral presentation and one for a poster. The abstracts were to be published on April 13, 2026. 2. Increased visibility towards partners and investors ASGCT is not just an academic conference. It also gathers potential partners, BD people, investors, and companies that closely follow new platforms. Therefore, “ASGCT profiling” can make more people aware of the technology, even without a deal coming the same day. ASGCT itself emphasizes that the meeting is the place to learn about new technology and build relationships in the field. 3. Narrative effect in the market When a small biotech company like Circio gets stage time at such an important conference, the market can start to treat it as a more serious platform case. It is not the same as revenues or clinical data in humans, but it can raise interest and make it easier to get meetings, media coverage, and further attention.- ·6 t sittenIt will be exciting to follow Circio on May 11-15, 2026 at ASGCT's annual conference in Boston. The ASGCT conference is described as the largest and most prestigious global gene and cell therapy conference. Circio is among a select few chosen for an oral scientific presentation. This will clearly strengthen Circio's position and at the same time provide opportunities for in-depth collaboration and partner dialogues. The content of Circio's upcoming presentation will be announced during April 13. It will be exciting - I'm looking forward to it. Have a good weekend everyone!
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q2 -tulosraportti
212 päivää sitten
‧37 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1 t sittenI'm very new to the game, but I've read up as much as I can on the stock. Nevertheless, I'm struggling to figure out what to do when it comes to when I should sell - yes, I can afford to lose the money, but it's still annoying. Does anyone have an opinion on what might happen this week, before Easter fully kicks off? I'm very keen to hold onto the stock as long as there is positive news
- 2 t sitten2 t sitten
- ·4 t sitten · MuokattuWhat do people think about CRNA now before Easter? I personally have rock-solid faith in CRNA, both in the short and long term. But do you think we'll see more buying pressure ig FOMO leading up to the Easter market close, or that people will secure profits and call it a day?
- ·6 t sittenI see that Collao finds it exciting to follow Circio at ASGCT's annual conference in Boston. Perhaps not everyone fully understands why. ASGCT profiling practically means that a company gains visibility and professional legitimacy at ASGCT, which is the largest and most central conference in gene and cell therapy. ASGCT describes the annual meeting as the largest and most comprehensive event in the field, with 7,000+ participants, 320+ exhibitors, and an audience that includes researchers, industry leaders, regulators, and clinicians. For Circio, it more specifically means three things: 1. Professional validation If an abstract is accepted, and especially if it is chosen for oral presentation, it is a mark of quality. Circio announced on March 18, 2026, that they had submitted two abstracts to ASGCT 2026, where one was chosen for oral presentation and one for a poster. The abstracts were to be published on April 13, 2026. 2. Increased visibility towards partners and investors ASGCT is not just an academic conference. It also gathers potential partners, BD people, investors, and companies that closely follow new platforms. Therefore, “ASGCT profiling” can make more people aware of the technology, even without a deal coming the same day. ASGCT itself emphasizes that the meeting is the place to learn about new technology and build relationships in the field. 3. Narrative effect in the market When a small biotech company like Circio gets stage time at such an important conference, the market can start to treat it as a more serious platform case. It is not the same as revenues or clinical data in humans, but it can raise interest and make it easier to get meetings, media coverage, and further attention.
- ·6 t sittenIt will be exciting to follow Circio on May 11-15, 2026 at ASGCT's annual conference in Boston. The ASGCT conference is described as the largest and most prestigious global gene and cell therapy conference. Circio is among a select few chosen for an oral scientific presentation. This will clearly strengthen Circio's position and at the same time provide opportunities for in-depth collaboration and partner dialogues. The content of Circio's upcoming presentation will be announced during April 13. It will be exciting - I'm looking forward to it. Have a good weekend everyone!
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 200 | - | - | ||
| 1 400 | - | - | ||
| 1 500 | - | - | ||
| 651 | - | - | ||
| 7 445 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2025 Q4 -tulosraportti 15.4. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 | ||
2023 Q3 -tulosraportti 9.11.2023 |
2025 Q2 -tulosraportti
212 päivää sitten
‧37 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2025 Q4 -tulosraportti 15.4. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 | ||
2023 Q3 -tulosraportti 9.11.2023 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1 t sittenI'm very new to the game, but I've read up as much as I can on the stock. Nevertheless, I'm struggling to figure out what to do when it comes to when I should sell - yes, I can afford to lose the money, but it's still annoying. Does anyone have an opinion on what might happen this week, before Easter fully kicks off? I'm very keen to hold onto the stock as long as there is positive news
- 2 t sitten2 t sitten
- ·4 t sitten · MuokattuWhat do people think about CRNA now before Easter? I personally have rock-solid faith in CRNA, both in the short and long term. But do you think we'll see more buying pressure ig FOMO leading up to the Easter market close, or that people will secure profits and call it a day?
- ·6 t sittenI see that Collao finds it exciting to follow Circio at ASGCT's annual conference in Boston. Perhaps not everyone fully understands why. ASGCT profiling practically means that a company gains visibility and professional legitimacy at ASGCT, which is the largest and most central conference in gene and cell therapy. ASGCT describes the annual meeting as the largest and most comprehensive event in the field, with 7,000+ participants, 320+ exhibitors, and an audience that includes researchers, industry leaders, regulators, and clinicians. For Circio, it more specifically means three things: 1. Professional validation If an abstract is accepted, and especially if it is chosen for oral presentation, it is a mark of quality. Circio announced on March 18, 2026, that they had submitted two abstracts to ASGCT 2026, where one was chosen for oral presentation and one for a poster. The abstracts were to be published on April 13, 2026. 2. Increased visibility towards partners and investors ASGCT is not just an academic conference. It also gathers potential partners, BD people, investors, and companies that closely follow new platforms. Therefore, “ASGCT profiling” can make more people aware of the technology, even without a deal coming the same day. ASGCT itself emphasizes that the meeting is the place to learn about new technology and build relationships in the field. 3. Narrative effect in the market When a small biotech company like Circio gets stage time at such an important conference, the market can start to treat it as a more serious platform case. It is not the same as revenues or clinical data in humans, but it can raise interest and make it easier to get meetings, media coverage, and further attention.
- ·6 t sittenIt will be exciting to follow Circio on May 11-15, 2026 at ASGCT's annual conference in Boston. The ASGCT conference is described as the largest and most prestigious global gene and cell therapy conference. Circio is among a select few chosen for an oral scientific presentation. This will clearly strengthen Circio's position and at the same time provide opportunities for in-depth collaboration and partner dialogues. The content of Circio's upcoming presentation will be announced during April 13. It will be exciting - I'm looking forward to it. Have a good weekend everyone!
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 200 | - | - | ||
| 1 400 | - | - | ||
| 1 500 | - | - | ||
| 651 | - | - | ||
| 7 445 | - | - |
Välittäjätilasto
Dataa ei löytynyt